Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Matthias Rueth is active.

Publication


Featured researches published by Matthias Rueth.


Journal of Medicinal Chemistry | 2011

Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase

Michael Prime; Stephen Martin Courtney; Frederick Arthur Brookfield; Richard W. Marston; Victoria Walker; Justin Warne; Andrew E. Boyd; Norman Kairies; Wolfgang von der Saal; Anja Limberg; Guy Georges; Richard A. Engh; Bernhard Goller; Petra Rueger; Matthias Rueth

The inhibition of Aurora kinases in order to arrest mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells has generated significant discussion within the literature. We report a novel class of Aurora kinase inhibitors based upon a phthalazinone pyrazole scaffold. The development of the phthalazinone template resulted in a potent Aurora-A selective series of compounds (typically >1000-fold selectivity over Aurora-B) that display good pharmacological profiles with significantly improved oral bioavailability compared to the well studied Aurora inhibitor VX-680.


Archive | 2007

Methods of inhibiting BTK and SYK protein kinases

David Michael Goldstein; Matthias Rueth


Archive | 2005

Novel pentafluorosulfanyl compounds

Birgit Bossenmaier; Walter-Gunar Friebe; Guy Georges; Matthias Rueth; Edgar Voss


Archive | 2005

Trycyclic heterocycles, their manufacture and use as pharmaceutical agents

Guy Georges; Bernhard Goller; Klaus-Peter Kuenkele; Anja Limberg; Ulrike Reiff; Petra Rueger; Matthias Rueth; Christine Schuell


Archive | 2005

NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS

Edward Boyd; Frederick Brookfield; Guy Georges; Bernhard Goller; Sabine Huensch; Petra Rueger; Matthias Rueth; Stefan Scheiblich; Christine Schuell; Der Saal Wolfgang Von; Justin Warne; Stefan Weigand


Archive | 2007

SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS

Guy Georges; Bernhard Goller; Anja Limberg; Petra Rueger; Matthias Rueth; Christine Schuell; Mark Stahl


Archive | 2013

Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases

Harald Duerr; Frank Herting; Christian Klein; Joerg Thomas Regula; Matthias Rueth; Kay-Gunnar Stubenrauch


Archive | 2013

Incretin receptor ligand polypeptide Fc-region fusion polypeptides and conjugates with altered Fc-effector function

Richard D. Dimarchi; Eike Hoffmann; Erhard Kopetzki; Matthias Rueth; Georg Tiefenthaler


Archive | 2006

Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents

Guy Georges; Bernhard Goller; Hans-Willi Krell; Anja Limberg; Ulrike Reiff; Petra Rueger; Matthias Rueth; Christine Schuell; Mark Stahl


Archive | 2004

Novel oxazoles, their manufacture and use as pharmaceutical agents

Birgit Bossenmaier; Walter-Gunar Friebe; Ulrike Reiff; Matthias Rueth; Edgar Voss

Collaboration


Dive into the Matthias Rueth's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge